← All Clearside Biomedical, INC filings

Clearside Biomedical, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CLSD
Clearside Biomedical, INC
10-K: Clearside Biomedical Reports 2024 Results, Faces Going Concern Uncertainty
Clearside Biomedical's 2024 10-K filing reveals ongoing losses and substantial doubt about its ability to continue as a going concern, despite positive clinical trial results and strategic partnerships.
NASDAQ
CLSD
Clearside Biomedical, INC
10-K: Clearside Biomedical 10-K Filing: Focus on Suprachoroidal Delivery and Pipeline Development
Clearside Biomedical's 10-K filing highlights its focus on suprachoroidal drug delivery, pipeline development, and strategic collaborations, while also detailing financial results and risks.